



Editor-in-Chief
Pedro T Ramirez (USA)

Associate Editors
Antonio Gonzalez (Spain)
Anna Fagotti (Italy)
Michael Frumovitz (USA)
Rene Pareja (Colombia)
Anuja Jhingran (USA)

Video Editor
Luis Chiva (Spain)

Social Media Editor
Ane Gerda Zahl Eriksson (Norway)

Managing Editor
Lindsey Struckmeyer (USA)

Editorial Office
International Journal of Gynecological Cancer, BMJ Journals
Two Hudson Square, 3rd Floor,
Hoboken, NJ 07030 USA
E: ijgc@jmeditorial.com

Production Editor
Hannah Martin
E: production.ijgc@bmj.com

Customer support
For general queries and support with
existing and new subscriptions:
W: support.bmj.com
T: +44 (0)20 7111 1105
E: support@bmj.com

Self-archiving and permissions
W: bmj.com/company/products/services/rights-and-licensing/
E: bmj.permissions@bmj.com

Disclaimer: The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

Copyright: © 2021 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

The *International Journal of Gynecological Cancer* (IJGC) is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

Lead Article

- 495** Role of radical hysterectomy in patients with early-stage high-grade neuroendocrine cervical carcinoma: a NeCTuR study

G Salvo, P Ramalingam, A Flores Legarreta, A Jhingran, N R Gonzales, G B Chisholm, M Frumovitz

Editorial

- 502** Rationale for the avoidance of parametrectomy and systematic lymphadenectomy in patients with early stages of neuroendocrine cervical cancer

D Cibula

Cervical Cancer

- 504** Oncological outcomes of laparoscopic radical hysterectomy versus radical abdominal hysterectomy in patients with early-stage cervical cancer: a multicenter analysis

J Rodriguez, J A Rauh-Hain, J Saenz, D O Isla, G J Rendon Pereira, D Odetto, F Martinelli, V Villoslada, I Zapardiel, L M Trujillo, M Perez, M Hernandez, J M Saadi, F Raspagliesi, H Valdivia, J Siegrist, S Fu, M Hernandez Nava, L Echeverry, F Noll, A Ditto, A Lopez, A Hernandez, R Pareja

- 512** Clinical features and prognostic factors of cervical villoglandular adenocarcinoma

J-H Chen, H Duan, X-B Yu, H-W Zhao, X Chen, P Li, Z-Q Li, B-X Li, L-Y Pan, X Yan, C Chen

- 518** Stage IVA cervical cancer: outcomes of disease related complications and treatment

B R Khulpateea, A Paulson, M Carlson, D S Miller, J Lea

- 524** Radiotherapy dose escalation on pelvic lymph node control in patients with cervical cancer

E Gogineni, B Bloom, F Diaz Molina, J Villella, A Goenka

Uterine Cancer

- 530** Long-term quality of life outcomes of women treated for early-stage endometrial cancer

S Sanjida, A Obermair, V Gebiski, N Armfield, M Janda

- 537** Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes

F Multinu, S Garzon, A L Weaver, M E McGree, E Sartori, F Landoni, P Zola, G Dinoi, G Aletti, M S Block, A Gadducci, A Mariani

Ovarian Cancer

- 545** Risk of second malignancy in patients with ovarian clear cell carcinoma

J M V Nguyen, D Vicus, S Nofech-Mozes, L T Gien, M Q Bernardini, M Rouzbahman, L Hogen

- 553** Physical activity levels among ovarian cancer survivors: a prospective longitudinal cohort study

T Jones, C Sandler, D Vagenas, M Janda, A Obermair, S Hayes

- 562** Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission

O Smaletz, G Ismael, M Del Pilar Estevez-Diz, I L O Nascimento, A L G de Moraes, G F Cunha-Junior, S J Azevedo, V A Alves, A M Moro, F P Yeda, M L dos Santos, I Majumder, E W Hoffman

Surgery

- 569** Impact of anesthesia technique on post-operative opioid use in open gynecologic surgery in an enhanced recovery after surgery pathway

J Lasala, G E Mena, M D Iniesta, J Cata, B Pitcher, W Wendell, A Zorrilla-Vaca, K Cain, M Basabe, T Suki, L A Meyer, P T Ramirez

- 575** Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists

M Lanner, T Nikolova, B Gutic, N Nikolova, A Pletnev, I Selcuk, D-E Vlachos, Z Razumova, N Bizzarri, C Theofanakis, P Lepka, I Kahramanoglu, S Han, S Nasser, S Molnar, D Hudry, R Montero-Macías, N de Lange, R Macuks, M F Hasanov, R Karimbayli, I Gagua, C Andrade, C Pardal, J Dotlic, R M Alvarez, M Hruđa, F Fruhauf, L Ekdahl, S L Antonsen, V Sukhin, A G Z Eriksson, E Gliozheni, R Delic, A Satanova, N Kovacevic, L Gristenko, S Babloyan, K Zalewski, R Bharathan

Medicine

- 585** Emergency department utilization by patients with gynecologic cancer in the United States

B B Albright, M K Delgado, N A Latif, R L Giuntoli, E M Ko, A F Haggerty

Reviews

- 594** Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy



A S V M van den Heerik, N Horeweg, S M de Boer, T Bosse, C L Creutzberg

- 605** Clear cell carcinoma of the ovary: a clinical and molecular perspective



Y Iida, A Okamoto, R L Hollis, C Gourley, C S Herrington

Clinical trials

- 617** A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial

A Gonzalez Martin, L Sanchez Lorenzo, N Colombo, R dePont Christensen, F Heitz, M Meirovitz, F Selle, T van Gorp, N Alvarez, J Sanchez, C Marqués

- 623** A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082)

A Furusawa, M Takekuma, K Mori, T Usami, E Kondo, S Nishio, K Nishino, Y Miyamoto, R Yoshimura, M Watanabe, M Mikami, T Enomoto

Case study

- 627** Recurrence of vulvar squamous cell carcinoma as an undifferentiated sarcomatoid carcinoma

C Comerio, M Jaconi, B Zambetti, M Paderno, M G Valente, A Buda

Corners of the world

- 631** An update on cervical cancer screening in Vanuatu

E R Allanson, V Velanova, I H Frazer, M McAdam, Cervical Cancer Foundation (Logistics Support), Vanuatu Ministry of Health, Sullivan Nicolaides Pathology, Frazer Family Foundation

Video articles

- 633** Laparoscopic radical pelvic dissection for safely removing a large cervical myoma

M Chen, J Li, X Yin, L Yao

- 635** PleurX indwelling pleural catheter for the treatment of recurrent pleural effusion in advanced ovarian cancer

F Boria, M Rodriguez-Perez, D Vázquez-Vicente, T Castellanos, E Chacon, L Chiva

Educational video lecture

- 637** Ultrasound, macroscopic and histological features of serous epithelial ovarian carcinomas

P Romeo, D Arciuolo, M C Moruzzi, F Moro

Pathology archives

- 639** Atypical polypoid adenomyoma

S Grindstaff, N Banet

Images

- 641** Giant port-site recurrence after laparoscopic-staging for endometrial cancer

L Chiva, A Gonzalez-Martin

Commentaries

- 642** What have we learned after four randomized controlled trials on neoadjuvant chemotherapy for ovarian cancer?

T P Batista, H-C Hsu

- 644** The IJGC Editorial Fellowship

M A Angeles, G Bhandoria, H-C Hsu, S E F Jones, J Kacperczyk-Bartnik, N Nair, F Noll, Z Razumova, A Strojna, Y L Wan, G H van Ramshorst

Electronic pages

- e1** Correction: *Adult primary cervical rhabdomyosarcomas: A Multicentric cross-national case series*
- e2** Correction: *Int J Gynecol Cancer 2020; 30: multiple articles*
- e3** Correction: *254 Robotic corpus cancer surgery: ten year mortality data from the UK epicentre in guildford*
- e4** Correction: *255 Mirrors trial: minimally invasive robotic surgery, role in optimal debulking ovarian cancer, recovery & survival*
- e5** Correction: *580 Surgical management of gynecologic cancers during the COVID-19 pandemic*